Difference between revisions of "Part:BBa K4165057"
Line 8: | Line 8: | ||
===Usage and Biology=== | ===Usage and Biology=== | ||
− | + | Switch 37 is used to mediate the activity of HTRA1. It is composed of 3 parts connected by different linkers; an HtrA1 PDZ peptide, a clamp of two targeting peptides for tau or amyloid beta, and a catalytic domain inhibitor. Activating HTRA1 requires a conformational change in the linker, eliminating the attached inhibitor from the active site. The conformational rearrangement can be mediated through the binding of affinity clamp to tau or beta-amyloid. This binding will result in a tension that detaches the inhibitor from the active site. | |
<!-- --> | <!-- --> | ||
Line 18: | Line 18: | ||
===Dry-Lab characterization=== | ===Dry-Lab characterization=== | ||
+ | <p style=" font-weight: bold; font-size:14px;"> Modeling </p> | ||
− | + | The switch was modeled by (Alphafold - Rosettafold - tRrosetta) and the top model was obtained from tRrosseta. | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
<html> | <html> | ||
<p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/switches/37.png" style="margin-left:200px;" alt="" width="500" /></p> | <p><img src="https://static.igem.wiki/teams/4165/wiki/parts-registry/switches/37.png" style="margin-left:200px;" alt="" width="500" /></p> | ||
</html> | </html> | ||
− | + | Figure 1. The 3D structure of switch 37 modelled by tRrosseta. |
Revision as of 18:14, 11 October 2022
HtrA1 Switch 37
This composite part consists of T7 promoter (BBa_K3633015), lac operator (BBa_K4165062), pGS-21a RBS (BBa_K4165016), 6x His-tag (BBa_K4165020), H1A (BBa_K4165000), GS Linker (BBa_K4165067), seed peptide (BBa_K4165012), GS Linker (BBa_K4165019), seed peptide (BBa_K4165012), GS Linker (BBa_K4165067), WAP inhibitor (BBa_K4165008), and T7 terminator (BBa_K731721).
Usage and Biology
Switch 37 is used to mediate the activity of HTRA1. It is composed of 3 parts connected by different linkers; an HtrA1 PDZ peptide, a clamp of two targeting peptides for tau or amyloid beta, and a catalytic domain inhibitor. Activating HTRA1 requires a conformational change in the linker, eliminating the attached inhibitor from the active site. The conformational rearrangement can be mediated through the binding of affinity clamp to tau or beta-amyloid. This binding will result in a tension that detaches the inhibitor from the active site.
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12INCOMPATIBLE WITH RFC[12]Illegal NheI site found at 589
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 572
Illegal AgeI site found at 308 - 1000COMPATIBLE WITH RFC[1000]
Dry-Lab characterization
Modeling
The switch was modeled by (Alphafold - Rosettafold - tRrosetta) and the top model was obtained from tRrosseta.
Figure 1. The 3D structure of switch 37 modelled by tRrosseta.